Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 13,22 € (-6,51 %). La mediana es de 14,54 € (+2,83 %).
| Comprar |
8 |
| Mantener |
16 |
| Vender |
2 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Avantor's strong Q2 figures and raised full-year outlook lift stock
Avantor beat analyst estimates in the second quarter on both revenue (USD 1.69 billion) and adjusted diluted EPS (USD 0.21). Management raised the full-year guidance for adjusted EPS to USD 0.80–0.83, which fueled the premarket price move. The positive reaction is seen as a sign that the restructuring program "Revival" is delivering initial financial improvements; the stock was trading at USD 13.00, still below its 52-week high. » Más en de.investing.com
Avantor gains traction under new management as stabilization begins
Longleaf Partners highlighted Avantor as a contributor in Q2 2026, noting signs of stabilization and new CEO Emmanuel Ligner's guidance for revenue growth and strong free cash flow generation in 2H26. Book-to-bill exceeded one and management has progressed on operational initiatives, including a redesigned VWR website and improved ship-to-order patterns in Bioprocessing. Avantor closed at $10.39 on July 10, has a market cap of $7.09 billion, and has seen mixed recent performance with a one-month gain but a large 52-week decline. » Más en finance.yahoo.com
Avantor names Ludovic Brellier EVP of Bioscience & Medtech Products and chief transformation officer
Avantor appointed Ludovic Brellier as Executive Vice President of Bioscience & Medtech Products and Chief Transformation Officer, effective May 1. Brellier will run growth and operations for the BMP business and lead the enterprise-wide Revival Management Office, drawing on his prior leadership at Danaher and Cytiva. Benoit Gourdier will remain through end of 2026 to ensure an orderly transition, and CEO Emmanuel Ligner said Brellier’s transformation experience will support the company’s strategic initiatives. » Más en finance.yahoo.com
Avantor: insider buying continues streak as life‑sciences industry reports net selling in Q1
A Barclays analysis shows that insiders in the life‑sciences and diagnostics industry sold shares totaling USD 187m in Q1/2026. Avantor led open‑market purchases (around USD 2.4m), marking its fourth consecutive quarter of insider buying. Natera reported mostly preplanned sales of about USD 123m; Medpace, Guardant Health and Twist were among the largest open‑market sellers. Overall, open‑market purchases of USD 2.9m were matched against sales of USD 33m. » Más en de.investing.com
Avantor appoints Ludovic Brellier as EVP and chief transformation officer
Avantor will appoint Ludovic Brellier as of May 1 as executive vice president for Bioscience & Medtech Products and chief transformation officer. He will take over the BMP business and lead the Revival Management Office, brings experience from Danaher/Cytiva and is expected to drive company-wide transformation and integration initiatives. Benoit Gourdier will remain with the company until no later than the end of 2026 to support the transition. The personnel move comes against the backdrop of a share price of $7.26 near its 52-week low, a six-month loss of 46% and analysts’ expectations of a return to profitability this year. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1499,34 M | 8,36 % |
| Beneficio bruto | 472,15 M | 5,24 % |
| Beneficio neto | 179,57 M | 129,61 % |
| EBITDA | 214,71 M | 146,59 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 9566,74 M € |
Número de acciones | 677,62 M |
Máximo/mínimo de 52 semanas | 15,85 € - 6,60 € |
| Dividendos | No |
Beta | 0,95 |
Ratio P/E | 31,01 |
Ratio PEG | -0,02 |
Ratio P/B | 1,80 |
Ratio P/S | 1,59 |
Perfil de la empresa
Avantor, Inc. proporciona productos y servicios a clientes de los sectores biofarmacéutico, sanitario, educativo y gubernamental, tecnologías avanzadas y materiales aplicados en las Américas, Europa, Asia, Oriente Medio y África. La empresa ofrece materiales y consumibles, como productos químicos de alta pureza y reactivos, productos y suministros de laboratorio, materiales de silicona formulados, excipientes personalizados, conjuntos personalizados de un solo uso, resinas y columnas de cromatografía de procesos, kits de preparación de muestras analíticas, productos de educación y microbiología, kits para ensayos clínicos, bombas peristálticas y puntas para manipulación de fluidos. También proporciona equipos e instrumentación, incluidos sistemas de filtración, sistemas de inactivación viral, incubadoras, instrumentos analíticos, evaporadores, congeladores de ultrabajas temperaturas, cabinas de seguridad biológica y suministros para entornos críticos. Además, la empresa ofrece servicios y adquisiciones especializadas que comprenden laboratorio y producción in situ, servicios clínicos, de equipos, de compras y abastecimiento, y de escalado y desarrollo de materiales biofarmacéuticos. Avantor, Inc. fue fundada en 1904 y tiene su sede central en Radnor, Pensilvania.
| Nombre | Avantor |
| CEO | Emmanuel Ligner |
| Sede | Radnor,
pa Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Herramientas y servicios de ciencias de la vida |
| Salida a bolsa | 17/05/2019 |
| Empleados | 13.500 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | AVTR |
Frankfurt | AVG.F |
Düsseldorf | AVG.DU |
SIX | AVG.SW |
München | AVG.MU |
Wien | AVTR.VI |